Acute Leukemia Working Party Business & Educational Meeting, Kraków

rok: 2018 czas trwania: 1 dni zakończenie: 2018-11-17

Serdecznie zapraszamy na spotkanie Advances in pre- and post-transplant management of acute lymphoblastic leukemia, które odbędzie się w dniach 16-17 listopada w Krakowie.


Friday, November 16th

10:00 – 18:00 Business meeting
20:00 Gala dinner

Saturday, November 17th

"Advances in pre- and post-transplant management of acute lymphoblastic leukemia"

Session 1 Chairs: Jordi Esteve & Zinaida Peric

9:00-9:25 Classification of ALL – focus on new molecular subtypes Przemyslaw Juszczynski (Warsaw, Poland)
9:25-9:50 First-line therapy of Ph-negative ALL: Current status and perspectives Renato Bassan (Venice, Italy)
9:50-10:15 First-line therapy of Ph-positive ALL: How much chemotherapy do we need? Philippe Rousselot (Versailles, France)
10:15-10:40 Supportive care in ALL Bipin Savani (Nashville, USA)
10:40-11:00 Coffee break

Session 2 Chairs: Frederic Baron & Fabio Ciceri

11:00-11:25 MRD – the strongest predictor of relapse in ALL Maria Gilleece (Leeds, UK)
11:25-11:50 Indications for alloHSCT in ALL. Current practice in European study groups Sebastian Giebel (Gliwice, Poland)

Session 3 Chairs: Gesine Bug & Beata Piatkowska-Jakubas

11:50-12:15 Donor type for alloHSCT in ALL Arnon Nagler (Tel-Hashomer, Israel)
12:15-12:40 Optimal conditioning for ALL. Does it exist? Alexandros Spyridonidis (Athens, Greece)
12:40-13:05 Maintenance therapy in Ph-negative ALL Ali Bazarbachi (Beirut, Lebanon)
13:05-14:00 Lunch break Session

4 Chairs: Annalisa Ruggeri & Christoph Schmid

14:00-14:25 Prophylactic/pre-emptive approaches after alloHSCT in Ph-positive ALL Anna Czyz (Wroclaw, Poland)
14:25-14:50 Relapsed/refractory ALL: BiTE antibodies Eolia Brissot (Paris, France)
14:50-15:15 Relapsed/refractory ALL: Immunotoxins Mathias Stelljes (Münster, Germany)

Session 5 Chairs: Francesco Lanza & Jaime Sanz

15:15-15:40 Machine learning for outcome prediction in acute leukemia Roni Shouval (Tel-Aviv, Israel)
15:40-16:05 Can CAR T-cells synergize with alloHSCT in lymphoid malignancies? Mohamad Mohty (Paris, France)
16:05-16:25 AutoHSCT as a part of the treatment continuum Norbert-Claude Gorin (Paris, France)
16:25-16:30 Conclusions

ikona Info Oficjalna strona konferencji

Wróć do kalendarza
kodowanie: projekt: